Hoogendoorn Mels, Olde Wolbers Judith, Smit Willem M, Schaafsma M Ronald, Jedema Inge, Barge Renee M Y, Willemze Roel, Falkenburg J H Frederik
Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Clin Cancer Res. 2005 Jul 15;11(14):5310-8. doi: 10.1158/1078-0432.CCR-04-2425.
In patients treated with allogeneic stem cell transplantation for advanced mantle cell lymphoma (MCL), complete sustained remissions have been observed illustrating susceptibility of MCL cells to a graft-versus-lymphoma effect. To potentiate this graft-versus-lymphoma effect, adoptive transfer of in vitro selected MCL-specific CTL can be an attractive approach. The lack of expression of costimulatory molecules on MCL cells hampers the generation of MCL-reactive T-cell responses. The purpose of this study was to modify MCL cells into antigen-presenting cells (APC) and to use these MCL-APCs to induce allogeneic MCL-reactive T-cell responses.
Interleukin (IL)-4, IL-10, CpG, and CD40 activation were tested for their capacity to up-regulate costimulatory molecules on MCL cells. Primary MCL cells or the modified MCL-APCs were then used to evaluate the induction of MCL-reactive T-cell responses in HLA-matched donors.
Ligation of CD40 on MCL cells was essential to up-regulate costimulatory molecules and to induce production of high amounts of IL-12. In contrast to primary MCL cells, MCL-APC cells as stimulators were capable of inducing CD8+ CTL lines from HLA class I-matched donors. High numbers of CTL clones could be generated capable of efficiently killing the primary MCL cells and MCL-APC but not donor-specific targets.
These results show the feasibility to generate primary allogeneic T-cell responses against MCL-APC, and may provide new immunotherapeutic tools to further exploit the graft-versus-lymphoma effect following allogeneic stem cell transplantation in patients with MCL.
在接受异基因干细胞移植治疗晚期套细胞淋巴瘤(MCL)的患者中,已观察到完全持续缓解,这表明MCL细胞对移植物抗淋巴瘤效应敏感。为增强这种移植物抗淋巴瘤效应,体外选择的MCL特异性CTL的过继性转移可能是一种有吸引力的方法。MCL细胞上共刺激分子的缺乏阻碍了MCL反应性T细胞应答的产生。本研究的目的是将MCL细胞改造为抗原呈递细胞(APC),并利用这些MCL-APC诱导同种异体MCL反应性T细胞应答。
测试白细胞介素(IL)-4、IL-10、CpG和CD40激活上调MCL细胞上共刺激分子的能力。然后使用原代MCL细胞或改造后的MCL-APC评估HLA匹配供体中MCL反应性T细胞应答的诱导情况。
MCL细胞上CD40的连接对于上调共刺激分子和诱导大量IL-12的产生至关重要。与原代MCL细胞不同,作为刺激物的MCL-APC细胞能够从HLA I类匹配供体诱导出CD8+CTL系。可以产生大量能够有效杀伤原代MCL细胞和MCL-APC但不能杀伤供体特异性靶标的CTL克隆。
这些结果表明产生针对MCL-APC的原发性同种异体T细胞应答是可行的,并可能提供新的免疫治疗工具,以进一步利用MCL患者异基因干细胞移植后的移植物抗淋巴瘤效应。